First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study

Table 3 Univariate and multivariate analyses for progression-free survival and overall survival

	Univariate analysis (simple Cox regression model)		Multivariate analysis (multiple Cox regression model without variable selection)
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Progression-free survival
Age^a	1.039 (0.441–2.449)	0.930	1.675 (0.630–4.457)	0.301
ECOG^b	1.729 (0.967–3.091)	0.065	1.324 (0.609–2.879)	0.479
IELSG risk
Low vs intermediate	1.983 (0.992–3.965)	0.053	2.384 (0.887–6.409)	0.085
Low vs high	2.716 (0.929–7.939)	0.068	1.867 (0.376–9.269)	0.445
With rituximab^c	0.949 (0.533–1.690)	0.860	0.766 (0.373–1.576)	0.470
With radiotherapy^d	0.468 (0.261–0.838)	0.110	0.404 (0.204–0.800)	0.009
Overall survival
Age	1.502 (0.574–3.933)	0.407	2.079 (0.650–6.651)	0.217
ECOG	2.036 (0.995–4.165)	0.052	1.049 (0.414–2.659)	0.920
IELSG risk
Intermediate vs low	4.992 (1.723–14.458)	0.003	6.079( 1.665–22.200)	0.006
High vs Low	8.228 (2.116–31.994)	0.002	6.879 (1.045–45.278)	0.045
With rituximab	1.267 (0.643–2.497)	0.493	0.871 (0.370–2.049)	0.752
With radiotherapy	0.577 (0.294–1.134)	0.110	0.466 (0.211–1.029)	0.058

^aAge of 60 years or older versus younger than 60 years
^†ECOG performance status 0–1 versus 2–4
^cFirst-line chemotherapy (methotrexate or teniposide) with or without rituximab
^dWith or without radiotherapy as a consolidation therapy after methotrexate or teniposide

ISSN: 1471-2407